Despite strong guidance and pipeline, AstraZeneca's stock dr...
Despite strong guidance and pipeline, AstraZeneca's stock dropped due to disappointing Q4 core EPS. The CEO, however, remains optimistic for 2024 growth, driven by global adoption of their medicines and new product investments.
AstraZeneca Shares Drop After Weak Quarterly Print Despite 2024 Growth Guidance -- Update
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment
Moomoo AI Official Account
Your AI assistant for discovering investment opportunities.
4070Followers
0Following
9078Visitors
Follow